Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 2/20 | 0.61 |
| ▸ | KMO | O15229 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | DAO | P14920 | 1/20 | 0.49 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 4/20 | 0.46 |
| ▸ | NPC1 | O15118 | 4/20 | 0.44 |
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.42 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7331551 | 0.81 | RECQL (0.69) | RECQLKMOCYP1A2DAOADRA2A | |
| SCHEMBL20083802 | 0.80 | CYP1A2 (0.62) | RECQLKMOCYP1A2DAOADRA2A | |
| SCHEMBL9934410 | 0.79 | RECQL (0.61) | RECQLKMOCYP1A2DAOADRA2A | |
| SCHEMBL29520779 | 0.79 | RECQL (0.61) | RECQLKMOCYP1A2DAOADRA2A | |
| SCHEMBL5389251 | 0.79 | RECQL (0.61) | RECQLKMOCYP1A2DAOADRA2A | |
| SCHEMBL13217 | 0.79 | RECQL (0.61) | RECQLKMOCYP1A2DAOADRA2A | |
| SCHEMBL730640 | 0.79 | RECQL (0.61) | RECQLKMOCYP1A2DAOADRA2A | |
| SCHEMBL3076519 | 0.79 | RECQL (0.61) | RECQLKMOCYP1A2DAOADRA2A | |
| SCHEMBL29520910 | 0.79 | RECQL (0.61) | RECQLKMOCYP1A2DAOADRA2A | |
| SCHEMBL6125449 | 0.79 | RECQL (0.61) | RECQLKMOCYP1A2DAOADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3398950-B1 | NOVEL KINASE INHIBITOR AGAINST WILD-TYPE EGFR AND MUTATED EGFR | PRECEDO PHARMACEUTICALS CO LTD (CN) | 2021-08-11 | — | — | EP | disclosed |
| US-10781214-B2 | Kinase inhibitor against wild-type and mutant EGFR | PRECEDO PHARMACEUTICALS CO., LTD. (CN) | 2020-09-22 | — | — | US | disclosed |
| US-20190010159-A1 | NOVEL KINASE INHIBITOR AGAINST WILD-TYPE AND MUTANT EGFR | PRECEDO PHARMACEUTICALS CO., LTD (CN) | 2019-01-10 | — | — | US | disclosed |
| EP-3398950-A1 | NOVEL KINASE INHIBITOR AGAINST WILD-TYPE EGFR AND MUTATED EGFR | Precedo Pharmaceuticals Co., Ltd. (CN) | 2018-11-07 | — | — | EP | disclosed |
| US-20150266839-A1 | CYCLIC AMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2015-09-24 | — | — | US | disclosed |
| US-20150225392-A1 | CYCLIC AMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2015-08-13 | — | — | US | disclosed |
| US-9072758-B2 | Cyclic amide derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2015-07-07 | — | — | US | disclosed |
| US-9040525-B2 | Cyclic amide derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2015-05-26 | — | — | US | disclosed |
| US-8765752-B2 | 3-hydroxyisothiazole 1-oxide derivatives | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2014-07-01 | — | — | US | disclosed |
| EP-2703394-A1 | NOVEL 3-HYDROXYISOTHIAZOLE 1-OXIDE DERIVATIVE | Mochida Pharmaceutical Co., Ltd. (JP) | 2014-03-05 | — | — | EP | disclosed |
| US-8629102-B2 | 3-hydroxyisothiazole 1-oxide derivatives | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2014-01-14 | — | — | US | disclosed |
| US-20130217690-A1 | NOVEL 3-HYDROXYISOTHIAZOLE 1-OXIDE DERIVATIVES | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2013-08-22 | — | — | US | disclosed |
| US-20130210721-A1 | NOVEL 3-HYDROXYISOTHIAZOLE 1-OXIDE DERIVATIVES | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2013-08-15 | — | — | US | disclosed |
| US-20130203739-A1 | CYCLIC AMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2013-08-08 | — | — | US | disclosed |
| US-8476287-B2 | 3-hydroxy-5-arylisothiazole derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2013-07-02 | — | — | US | disclosed |
| US-8455500-B2 | 3-hydroxy-5-arylisoxazole derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2013-06-04 | — | — | US | disclosed |
| EP-2518060-A1 | NOVEL 3-HYDROXY-5-ARYLISOTHIAZOLE DERIVATIVE | Mochida Pharmaceutical Co., Ltd. (JP) | 2012-10-31 | — | — | EP | disclosed |
| EP-2495238-A1 | NOVEL 3-HYDROXY-5-ARYLISOXAZOLE DERIVATIVE | Mochida Pharmaceutical Co., Ltd. (JP) | 2012-09-05 | — | — | EP | disclosed |
| US-20120220772-A1 | NOVEL 3-HYDROXY-5-ARYLISOXAZOLE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2012-08-30 | — | — | US | disclosed |
| US-20120157459-A1 | NOVEL 3-HYDROXY-5-ARYLISOTHIAZOLE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190010159-A1 | NOVEL KINASE INHIBITOR AGAINST WILD-TYPE AND MUTANT EGFR | EGFR, ERBB2, ERBB3 | RECQL 1919/4885KMO 4703/4885CYP1A2 4127/4885 |
| US-20150266839-A1 | CYCLIC AMIDE DERIVATIVE | GPR119, NR0B1, NR4A1 | RECQL 3666/4885KMO 2964/4885CYP1A2 2856/4885 |
| US-20130210721-A1 | NOVEL 3-HYDROXYISOTHIAZOLE 1-OXIDE DERIVATIVES | GPR119, GPR27, GPR65 | RECQL 4723/4885KMO 2376/4885CYP1A2 3037/4885 |
| US-20130217690-A1 | NOVEL 3-HYDROXYISOTHIAZOLE 1-OXIDE DERIVATIVES | GPR119, GPR27, GPR65 | RECQL 4723/4885KMO 2376/4885CYP1A2 3037/4885 |
| US-20150225392-A1 | CYCLIC AMIDE DERIVATIVE | GPR119, NR0B1, NR2C2 | RECQL 4250/4885KMO 3048/4885CYP1A2 1794/4885 |
| US-10781214-B2 | Kinase inhibitor against wild-type and mutant EGFR | EGFR, ERBB2, ERBB3 | RECQL 2087/4885KMO 4713/4885CYP1A2 4054/4885 |
| US-20120157459-A1 | NOVEL 3-HYDROXY-5-ARYLISOTHIAZOLE DERIVATIVE | GPR119, GPR27, NR0B1 | RECQL 4161/4885KMO 2245/4885CYP1A2 3016/4885 |
| US-20120220772-A1 | NOVEL 3-HYDROXY-5-ARYLISOXAZOLE DERIVATIVE | GPR119, GPR27, NR0B1 | RECQL 4055/4885KMO 1918/4885CYP1A2 2356/4885 |
| US-20130203739-A1 | CYCLIC AMIDE DERIVATIVE | GPR119, NR0B1, NR2C2 | RECQL 4381/4885KMO 2873/4885CYP1A2 1813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.